Pasithea Therapeutics Corp (KTTA)vsModerna Inc (MRNA)
KTTA
Pasithea Therapeutics Corp
$0.50
-1.96%
HEALTHCARE · Cap: $19.39M
MRNA
Moderna Inc
$143.77
-1.99%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 457809% more annual revenue ($2.23B vs $486,560). KTTA leads profitability with a 0.0% profit margin vs -141.4%. KTTA earns a higher WallStSmart Score of 38/100 (F).
KTTA
Hold38
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KTTA.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.77
$8.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 1498.0% year-over-year
Safe zone — low bankruptcy risk
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : KTTA
The strongest argument for KTTA centers on Price/Book, Revenue Growth, Altman Z-Score. Revenue growth of 1498.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : KTTA
The primary concerns for KTTA are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
KTTA profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
KTTA is growing revenue faster at 1498.0% — sustainability is the question.
KTTA generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
KTTA scores higher overall (38/100 vs 21/100) and 1498.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pasithea Therapeutics Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?